BioCentury | Nov 7, 2020
Targets & Mechanisms

Product profiles that could make interferons effective against COVID-19

The recent failure of IFNβ in WHO’s master protocol trial for COVID-19 notwithstanding, there are plenty of reasons to suspect that interferons should be effective treatments for the infection. An analysis...
BioCentury | Oct 3, 2020
Product Development

Oral drugs and treatments for life-threatening diseases stand out among new product launches

Despite the challenge of introducing a drug to the market during the COVID-19 pandemic, sales of nearly all new product launches increased in 2Q20 versus 1Q, with drugs to treat life-threatening conditions and oral products...
BioCentury | Aug 20, 2020

Pandemic could give advantage to newly approved MS latecomer ofatumumab

With FDA’s approval of Kesimpta ofatumumab for multiple sclerosis, Novartis could become the latest company to reap the added benefits of launching a drug with a convenient route of administration during the pandemic.  FDA approved...
BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

BeiGene’s BTK inhibitor gets first China approval BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) said China’s National Medical Products Administration approved Brukinsa zanubrutinib in two cancer indications: chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma...
BioCentury | Mar 8, 2019
Targets & Mechanisms

Oral insulin innovation

While clinical data suggest an oral insulin product may finally be within reach, the technology struggles to compete with injectables on price and efficacy. A handful of academics and companies are pushing preclinical innovation in...
BioCentury | Aug 4, 2018

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
BioCentury | Oct 12, 2017
Product R&D

Artificial mini proteins

Virvio Inc. has spun out of a group from the University of Washington to develop artificial mini proteins as novel influenza therapeutics. The mini proteins, typically ranging between 30 and 50 amino acids in length,...
BioCentury | Aug 30, 2010
Product Development

Environmental Activism

In the realm of cancer drug development, Johnson & Johnson is not the first or even second name that comes to mind, even though the company has about $3.5 billion in oncology sales each year...
BioCentury | May 25, 2009
Clinical News

Elagolix: Phase II data

Follow-up data from the Phase II PETAL trial showed that elagolix sustained safety and efficacy after treatment was stopped. Patients received 150 mg once-daily elagolix, 75 mg twice-daily elagolix or Depo-subQ provera 104 for 24...
BioCentury | Sep 15, 2008
Product Development

The elagolix fix

All marketed endometriosis drugs have problematic side effects, especially when taken long term. Doctors would like to have a drug that can be taken safely over a long period of time, and Neurocrine Biosciences Inc....
Items per page:
1 - 10 of 13